1,263 reports of this reaction
3.4% of all TOBRAMYCIN reports
#6 most reported adverse reaction
CYSTIC FIBROSIS is the #6 most commonly reported adverse reaction for TOBRAMYCIN, manufactured by Viatris Specialty LLC. There are 1,263 FDA adverse event reports linking TOBRAMYCIN to CYSTIC FIBROSIS. This represents approximately 3.4% of all 37,207 adverse event reports for this drug.
Patients taking TOBRAMYCIN who experience cystic fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYSTIC FIBROSIS is moderately reported among TOBRAMYCIN users, representing a notable but not dominant share of adverse events.
In addition to cystic fibrosis, the following adverse reactions have been reported for TOBRAMYCIN:
The following drugs have also been linked to cystic fibrosis in FDA adverse event reports:
CYSTIC FIBROSIS has been reported as an adverse event in 1,263 FDA reports for TOBRAMYCIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYSTIC FIBROSIS accounts for approximately 3.4% of all adverse event reports for TOBRAMYCIN, making it a notable side effect.
If you experience cystic fibrosis while taking TOBRAMYCIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.